Status:
COMPLETED
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
Lead Sponsor:
University of Turin, Italy
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
A total of 40 Multiple Myeloma (MM) patients at clinical relapse who progressed during Proteasome Inhibitors (PIs) or Immunomodulating Drugs (IMiDs)-based therapies and who are assigned to antiCD38-ba...
Detailed Description
Aim 1: Evaluation of cell-intrinsic mechanisms on BM. 1. Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) will be performed on marker CD138+ purified cells to evaluate their genomic pro...
Eligibility Criteria
Inclusion
- MM patients at clinical relapse who progressed during PIs or IMiDs-based therapies
- Patients assigned to antiCD38-based salvage treatments
- Patients with measurable disease
Exclusion
- No criteria
Key Trial Info
Start Date :
July 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 10 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03848676
Start Date
July 1 2018
End Date
December 10 2024
Last Update
December 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Torino, TO, Italy, 10126